Home>>Signaling Pathways>> Microbiology & Virology>> Reverse Transcriptase>>Islatravir (MK-8591)

Islatravir (MK-8591) (Synonyms: 4’Ed2FA, 4′-ethynyl-2-fluoro-2′-Deoxyadenosine, EFDA, MK-8591)

Catalog No.GC32306

Islatravir (MK-8591) (MK-8591) is a potent anti-HIV-1 agent, acting as a nucleoside reverse transcriptase inhibitor, with EC50s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively.

Products are for research use only. Not for human use. We do not sell to patients.

Islatravir (MK-8591) Chemical Structure

Cas No.: 865363-93-5

Size Price Stock Qty
10mM (in 1mL DMSO)
$413.00
In stock
5mg
$378.00
In stock
10mg
$612.00
In stock
25mg
$1,350.00
In stock
50mg
$2,250.00
In stock
100mg
$3,713.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Islatravir (MK-8591) is a potent anti-HIV-1 agent, acting as a nucleoside reverse transcriptase inhibitor, with EC50s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively.

Islatravir (MK-8591) (4'Ed2FA) is a potent anti-HIV-1 agent, acting as a nucleoside reverse transcriptase inhibitor, with EC50s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively[1].

[1]. Ohrui H, et al. 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity. Chem Rec. 2006;6(3):133-43.

Reviews

Review for Islatravir (MK-8591)

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Islatravir (MK-8591)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.